drugset / Trial / NCT00589381
Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma
Phase 1
Completed
30 enrolled
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI) · collab
Non-randomizedOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-12
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fenretinide | Small molecule | 800 mg/m2 | Oral |
| Subject | fenretinide | Small molecule | 1000 mg/m2 | Oral |